You're Not Weak. It May Be Rebound.

A rough night after lowering a dose can feel like proof that you needed the medicine. It may be rebound. It may also be withdrawal, recurrence, or more than one process at once.

This is Part 3 of a five-part series on sleep and mental health. The other parts cover Less Time in Bed, More Consolidated Sleep, The Harder You Try, the Further It Gets, He Can’t Fall Asleep. It May Not Be Defiance, and Sleep Was the First Thing to Change.

You lower a medicine taken for sleep. That night is rough. Maybe the next is worse. It can feel as if your body has betrayed you. The bad sleep may seem to prove you can never stop.

It proves neither. Sleep can worsen for several reasons. These include rebound insomnia, withdrawal, return of the old insomnia, or a new sleep problem. More than one can occur. The exact medicine matters. So do timing, other symptoms, and the reason it was prescribed. This article will help you sort those possibilities. It will not give you a taper schedule. If you take a benzodiazepine often, do not stop it on your own. Abrupt withdrawal can be dangerous.1

Key takeaways

• Physical dependence can happen during appropriate prescribed use. It is not weakness, and it is not automatically addiction.

• “Sleeping pill” is not one drug class. Benzodiazepines and Z-drugs need one set of questions. Orexin blockers, other medicines, supplements, alcohol, and cannabis may need others.

• A bad night after a reduction may be rebound. It may also be withdrawal, recurrence, reduced oversedation, or another sleep or health problem.

• Cognitive behavioral therapy for insomnia, called CBT-I, can treat the insomnia that is present during a taper. It may help some people stop a medicine, but it is not a guarantee.

• A good plan is shared, monitored, and adjustable. A pause or a safer lower dose can be a reasonable outcome.

Zoom

The first question is not “How fast?”

The first question is: What exactly are you taking, and why?

Bring the bottle, not just the phrase “sleeping pill.” A bedtime medicine may treat more than sleep. It may treat panic, seizures, pain, depression, bipolar disorder, or psychosis. Changing it can affect that condition too.

List prescriptions, OTC products, supplements, alcohol, cannabis, and nonprescribed products. Include opioids, antihistamines, muscle relaxants, gabapentinoids, antipsychotics, and antidepressants that add sedation or change risk. This is medication reconciliation, not a confession.

Rebound, recurrence, and withdrawal are different

These words are often mixed together. They should not be.

Rebound insomnia

Rebound means sleep is briefly worse than it was before treatment. It occurs after a medicine is reduced or stopped. You need some idea of the old baseline. One difficult night does not establish it.

Some short trials found worse sleep mainly on the first night after stopping. The pattern differed by benzodiazepine or Z-drug and by studied dose. The trials enrolled selected people. They cannot tell us what will happen after years of use.2

Recurrence

Recurrence means the old insomnia returns. The medicine may have reduced symptoms without changing what kept them going. The old pattern may then come back.

The picture may also have changed. Sleep apnea, restless legs, pain, or mood symptoms can now contribute. So can body-clock delay, shift work, substances, or another medicine.

Withdrawal

Withdrawal means new symptoms occur as the body adjusts to less medicine. Insomnia may be one symptom. With benzodiazepines, other signs may include anxiety, tremor, sweating, nausea, confusion, seizures, or delirium. Many signs overlap with anxiety and insomnia. Timing alone may not name the process.1

Some people report symptoms beyond the expected acute period. The 2025 U.S. guideline recognizes this possibility but notes limited evidence about frequency, boundaries, and treatment. Persistent symptoms deserve care and a fresh differential diagnosis, not dismissal or automatic attribution to withdrawal.

Physical dependence is not addiction

Physical dependence is a body adaptation. It can develop during prescribed benzodiazepine use, sometimes within weeks. A reduction may then cause withdrawal. Addiction or sedative use disorder involves impaired control or compulsive use despite harm. They can coexist, but they are not synonyms.1

Long-term use does not prove bad character or bad care. A medicine may have helped. The balance may later change with health, age, new medicines, or daily demands. Review is care, not a verdict.

A “sleeping pill” is not one kind of medicine

No table can decide how to stop a medicine. It shows why the ingredient comes before the plan.

One label-specific exception matters

General advice often says, “Never stop a sleep medicine suddenly.” That is too broad.

Current FDA boxed warnings name zolpidem, eszopiclone, and zaleplon. If one causes a complex sleep behavior, stop that product at once and contact a clinician. Examples include sleepwalking or sleep-driving while not fully awake. Serious injury and death have occurred. A person with a prior event should not take that product again.3

That instruction does not apply to every medicine or decide what to do with another sedative. Each product keeps its own rule. Contact the prescriber or pharmacist promptly. Use emergency care for injury, inability to awaken, breathing trouble, or suspected overdose.

What the CBT-I evidence really shows

CBT-I is a multicomponent chronic-insomnia treatment, not a sleep-hygiene handout. Article 1 owns the full explanation. Here, the question is whether it helps during medication reduction.

Small older-adult trials favored adding CBT-I to a supervised benzodiazepine taper. A 2003 trial enrolled 65 people. After treatment, 77% with combined care and 38% with taper alone had stopped. At 12 months, the results were 70% and 24%.6 A 2004 trial enrolled 76 long-term users. After treatment, 85% with combined care had stopped. The results were 48% with taper and 54% with CBT-I alone. Sleep improved more in the CBT-I groups.7

A 2019 review combined eight trials. It found a short-term stopping advantage and better insomnia with CBT-I plus taper. The 12-month estimate was unclear.8

Newer evidence is more cautious. A 2024 U.S. trial in 188 adults age 55 or older compared two programs that both included CBT-I and tapering. A specialized masked-dose program improved six-month discontinuation, 73.4% versus 58.6%, but not insomnia severity. It did not test CBT-I against no CBT-I.9

A Belgian primary-care trial found no blended-care advantage. One-year urine-confirmed stopping was 18% versus 20%.10 A 2025 trial in 47 older adults found similar results with or without CBT-I. CBT-I improved reported sleep quality. It did not improve measured sleep structure or thinking skills.11

In a 2025 review, 49 trials tested many ways to help people stop. The authors judged the evidence low certainty. They found no strong case for most methods when grouped broadly. Patient teaching, drug review, and pharmacist teaching may help.12

The fair conclusion is this: CBT-I can treat insomnia during a taper. It may help selected people stop a medicine. It does not promise that result. Stopped the medicine is not the same outcome as slept better. Both outcomes matter. So do daytime function and safety.

The Long Switchback

Think of a mountain path that descends through switchbacks. The turns allow time to see the terrain, check footing, and change the route. A straight drop may look faster, but it can be unsafe.

This is only a teaching image. It is not a dose formula. Every medicine does not use the same path. The route may pause. It may end at a safer lower dose rather than zero. Progress is not always a downward line.

The 2025 U.S. benzodiazepine guide says a personal process may take months or longer. It allows a person to stay at a lower dose. This may fit when more reduction would bring more risk than benefit.1 A pause gives the team information. It is not failure.

What a real taper process includes

A taper is a care process, not a percentage copied from the internet.

1. Name the medicine. Confirm ingredient, formulation, pattern, duration, and reason.

2. Reconcile all substances. Include prescriptions, OTC products, alcohol, cannabis, supplements, and nonprescribed products.

3. Review benefit and risk. Include sleep, pain, breathing, falls, driving, pregnancy, seizures, and past reductions.

4. Choose the safest setting. Most benzodiazepine tapers occur outpatient. A past withdrawal seizure or delirium raises concern. So do unstable illness, overdose risk, and an unsafe home. These may require closer care.1

5. Treat what the medicine was covering. It may be insomnia, panic, pain, sleep apnea, or restless legs. Mood, body-clock timing, or substance use may also need care.

6. Agree on the goal. The goal may be a full stop or a lower dose. No current change may also fit some cases.

7. Make planned changes with monitoring. The prescriber chooses the amount, timing, formulation, and review interval. The patient reports what happened.

8. Adjust the process. If symptoms significantly interfere, the clinician may slow, pause, or revise the plan. Do not improvise rescue doses or switch medicines on your own.

9. Continue support. Insomnia, another condition, or withdrawal symptoms may need follow-up after the final dose.

Essential ingredients

What to do this week

The goal this week is preparation, not a dose change.

Observable target: build one accurate record of what you take and what happens during a usual week.

Short baseline: record seven days. Note the product and time taken. Note sleep onset, major waking, morning alertness, and any new symptom. Do not calculate a taper.

Choose no more than three actions:

1. Photograph every prescription and OTC label you use for sleep, anxiety, pain, or nighttime symptoms.

2. Add alcohol, cannabis, caffeine, nicotine, supplements, and “as needed” products to the list.

3. Book a medication-review visit with the prescriber or pharmacist. Ask who will own the plan and how to reach them between visits.

Time and materials: about 15 minutes, one paper or phone note, and one appointment request.

Minimum version on a low-capacity day: photograph each label. Write, “I want to review sleep benefit, withdrawal risk, and my options.”

If you miss a day of tracking, restart with the next actual dose. At review, decide whether to continue, simplify, adapt, or get more help.

Coupled patient and family job box

Your job

• Share the full list, including products you use only sometimes.
• Help choose the goal and follow only the agreed plan.
• Report sleep, possible withdrawal, daytime function, and safety as separate lanes.
• Call when symptoms cross the thresholds you agreed on.

Your family’s job

• Participate only with your consent, unless immediate safety is at stake.
• Use neutral language. Help with rides or appointments.
• Support CBT-I if it is part of the plan.
• Notice breathing trouble, severe confusion, seizures, unsafe behavior, falls, or marked mood change.
• Ask what help is wanted instead of grading each night.

What neither of you has to do

Neither person has to prove strength through suffering. The family does not hide, discard, withhold, add, or share medicine. It does not create a faster schedule, urge rescue dosing, call dependence addiction, or become the prescriber.

When the plan needs professional help

Review the plan if symptoms interfere. Also review it if sleep or function worsens. Do the same if the goal no longer fits, access fails, or either person feels unsafe.

Bad-week decoder

Words you can use

Patient to prescriber: “I want to review the exact medicine and why I take it. I also want to know my withdrawal risk. What goal fits me?”

Family member: “This looks like a hard week, not a character test. Do you want help calling the clinician or arranging a ride?”

Patient to pharmacist: “Can we review sedating products, duplicate ingredients, interactions, and the current label instructions?”

Measure real-life progress in five lanes

Do not let dose alone become the grade.

1. Medicine: amount and nights used, planned versus unplanned changes, and rescue or substitute use.

2. Insomnia: time to fall asleep, wake time during the night, sleep satisfaction, and distress.

3. Possible withdrawal: physical, sensory, emotional, and thinking changes.

4. Function: alertness, fatigue, falls, driving, work, caregiving, mood, and quality of life.

5. Safety and burden: note near misses and breathing concerns. Also note cost, conflict, visit load, and whether the plan still works.

A lower dose with worse driving safety is not progress. Neither is full discontinuation with severe untreated insomnia. Review the lanes together.

Troubleshooting

Access at three levels

Start today

Make the medication and substance inventory. It costs nothing and does not require a dose change.

Lower-cost support

Ask a pharmacist, primary-care clinic, community health center, insurer, or training clinic about medication review and CBT-I. Group, telehealth, and guided digital care may lower cost, but privacy, internet needs, and evidence differ. Ask whether a clinician monitors medication-change safety.

Formal care

A prescriber should own the medication plan. A pharmacist can reconcile products. A CBT-I clinician can treat insomnia. Specific risks may need addiction medicine, toxicology, psychiatry, neurology, sleep medicine, obstetrics, or geriatrics.

Ask about contact, language and disability access, transport, pharmacy supply, insurance, and backup coverage. The plan must fit housing, work, caregiving, and internet limits. Access barriers are not lack of motivation.

A simple coordination plan

Write one line for each item:

• Goal: full discontinuation, lower dose, or risk-benefit review without a current change.
• Baseline: medicine pattern, insomnia, withdrawal-like symptoms, function, and safety.
• Strategy: prescriber-managed changes plus treatment for the underlying condition.
• Owner: one named prescriber; pharmacist and CBT-I clinician roles if involved.
• Frequency: when records are reviewed and how contact occurs after a change.
• Review date: the next decision point, not a promised finish date.
• Consent: what a family member may know or do, and what stays private.
• Escalation: emergency, same-day, and routine thresholds.

Share only the information needed for the plan. Consent to family involvement can be changed.

Three levels of help

Emergency help now

Call 911 for a seizure or severe confusion. Call for unsafe hallucinations, extreme agitation, fainting, or breathing trouble. Call if the person cannot awaken or may have overdosed. Also call for suicidal intent, an immediate plan, or another immediate danger. In the United States, call or text 988 for crisis support. For suspected poisoning, call Poison Control at 1-800-222-1222 after urgent needs are met.13

Same-day clinical evaluation

Call the prescriber the same day for growing tremor, sweating, palpitations, or marked restlessness. Also call for repeated vomiting, severe panic, a fast mood decline, a fall, or an injury. Very little sleep with unusual energy, racing thoughts, fast speech, or risky acts also needs same-day care. Do not drive if sleepy. Arrange another ride.

Pretaper and routine review

Plan more closely after a past withdrawal seizure or delirium. Do the same for uncontrolled seizures, long daily use, high doses, a short-acting benzodiazepine, or past severe alcohol withdrawal. Opioids, several sedatives, unstable illness, substance use disorder, pregnancy, frailty, or an unsafe home also matter. These do not always mean inpatient care. They mean choosing the safest setting before the next change.

Frequently asked questions

FAQ-A2-1: Does one bad night after a dose reduction prove rebound insomnia?

No. Rebound means sleep is briefly worse than the old baseline. One bad night could be return of insomnia, withdrawal, normal variation, less oversedation, worry, or another sleep problem. Record the timing and other symptoms. Review them with the prescriber.

FAQ-A2-2: Is physical dependence the same as addiction?

No. Physical dependence is a body change during use. It can happen when a medicine is taken as prescribed. A reduction may then cause withdrawal. Addiction or sedative use disorder involves poor control or compulsive use despite harm. A person can have one, both, or neither.

FAQ-A2-3: Should every sleeping medicine be tapered?

No single rule fits every product. Benzodiazepines should not be stopped abruptly when physical dependence is possible. Some newer insomnia medicines did not show a clear withdrawal signal in trials. Current labels for zolpidem, eszopiclone, and zaleplon also require immediate discontinuation after a complex sleep behavior. Check the exact product with the prescriber or pharmacist.

FAQ-A2-4: Can CBT-I help while I reduce a sleep medicine?

It can treat chronic insomnia during a taper. It may help some long-term benzodiazepine or zolpidem users stop in the short term. The trials are mixed. Lasting benefit is less clear, and access varies. CBT-I does not replace a safety review or care for the root condition.

FAQ-A2-5: What should a partner or family member do during a hard week?

With consent, use neutral words and help with rides or visits. Support the agreed sleep care. Know when to call. Do not hide, withhold, add, or share medicine. Do not speed the plan, urge rescue doses, or call dependence addiction.

This article is for education and is not a diagnosis or an individual treatment plan. Sleep problems can have more than one cause. A qualified clinician can help you choose care that fits your health, medicines, schedule, and safety needs. Do not start, stop, taper, or change a prescription medicine based on this article.

This article is for education and is not a diagnosis or an individual treatment plan. Sleep problems can have more than one cause. A qualified clinician can help you choose care that fits your health, medicines, schedule, and safety needs. Do not start, stop, taper, or change a prescription medicine based on this article.

Tools you can use

The following tools are copy-ready but should be published as a linked companion resource so the core page remains calm. They contain no dose schedule.

Tool 1: Medication and substance inventory

Bring: containers or clear photos, pharmacy list, recent discharge list, and contact information for every prescriber.

Tool 2: Taper-conversation sheet

My reason for reviewing this medicine:

What it still helps:

What worries or burdens me:

My original indication:

My preferred goal today: full discontinuation, lower dose, no current change, or unsure.

Conditions that need treatment during the process: insomnia, anxiety, mood, trauma, pain, breathing, restless legs, circadian timing, seizure disorder, substance use, or other.

People and roles: coordinating prescriber, pharmacist, CBT-I clinician, specialist, support person with consent.

Monitoring lanes: medicine, insomnia, possible withdrawal, function, safety and burden.

How I reach the team after a change:

Same-day call signs we agreed on:

Emergency signs we agreed on:

Next review date:

Tool 3: Bad-week household plan

Before a change

• Ask the patient what help is wanted and what information may be shared.
• Put the prescriber, pharmacy, 988, 911, and Poison Control numbers in one place.
• Plan rides and reduce avoidable hazardous tasks if daytime impairment is possible.
• Choose one check-in time rather than repeated questions.

During a hard week

• Say: “This is information for the plan, not a grade.”
• Record what changed, when, and which symptoms appeared.
• Help with meals, transport, childcare, or calls only as agreed.
• Follow the call threshold. Do not debate whether the symptom is “real.”

Do not

• Hide, discard, withhold, add, or share medicine.
• Create a faster plan or recommend a rescue dose.
• Substitute alcohol, cannabis, antihistamines, supplements, or another person’s prescription.
• Call physical dependence addiction.
• Make a family member the only person responsible for safety.

Tool 4: Family do-and-do-not card

Tool 5: Prescriber and pharmacist questions

1. What is the exact ingredient, formulation, and original indication?
2. Which current FDA label and boxed warnings apply?
3. What raises my withdrawal or overdose risk?
4. Which other products add sedation, anticholinergic burden, respiratory risk, or seizure risk?
5. Does the original condition need another treatment before a change?
6. Is CBT-I appropriate, and what format is available?
7. Is full discontinuation the goal, or would a lower dose be reasonable?
8. Who owns the plan when more than one clinician prescribes sedating medicines?
9. What should I record after a change?
10. Which symptoms mean pause, same-day contact, emergency care, or Poison Control?
11. How will pregnancy, liver or kidney function, breathing disease, falls, cognition, work, or driving change the plan?
12. What happens after the final dose if insomnia or another condition remains?

Tool 6: Five-lane progress tracker

Use one short entry per day for several days around a planned change. Do not use the sheet to create a dose change. If tracking increases fear or conflict, reduce it to medicine, function, and safety only.

Tool 7: One-page call-threshold card

911 now: seizure; severe confusion or delirium; unsafe hallucinations or psychosis; extreme agitation with inability to stay safe; fainting; trouble breathing; inability to awaken; suspected overdose; suicidal intent or an immediate plan.

988: call or text 988 for suicide or mental-health crisis support in the United States. Use 911 for immediate danger.

Poison Control: 1-800-222-1222 for suspected poisoning. Use 911 first for trouble breathing, seizure, collapse, or inability to awaken.

Same-day clinician: escalating tremor, sweating, palpitations, marked restlessness, repeated vomiting or dehydration, severe panic, rapidly worsening mood, fall or injury, or very little sleep with unusual energy, racing thoughts, rapid speech, or impulsive behavior.

Routine plan review: poor fit, high burden, access barrier, no progress, persistent insomnia, or unclear goals.

Related reading

• Less Time in Bed, More Consolidated Sleep
• The Harder You Try, the Further It Gets
• He Can’t Fall Asleep. It May Not Be Defiance
• Sleep Was the First Thing to Change
• Sleep Medications Demystified
• GABA, Benzodiazepines, Anxiety and Sleep
• Orexin, Insomnia and Narcolepsy Medicines
• Melatonin: a Clock Signal, Not a Sleeping Pill

References

1. Brunner E, Chen CYA, Klein T, et al. Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits. Journal of General Internal Medicine. 2025;40(12):2814-2859. doi:10.1007/s11606-025-09499-2. PMID: 40526204. Official ASAM guideline page.

2. Watson NF, Benca RM, Krystal AD, McCall WV, Neubauer DN. Alliance for Sleep Clinical Practice Guideline on Switching or Deprescribing Hypnotic Medications for Insomnia. Journal of Clinical Medicine. 2023;12(7):2493. doi:10.3390/jcm12072493. PMID: 37048577. PMCID: PMC10095217.

3. U.S. Food and Drug Administration. Certain Prescription Insomnia Medicines: New Boxed Warning Due to Risk of Serious Injuries Caused by Sleepwalking. April 30, 2019. Accessed August 31, 2026. Official FDA communication. See also current labels for Ambien, Lunesta, and zaleplon.

4. U.S. National Library of Medicine. Current prescribing information for Belsomra, suvorexant, Dayvigo, lemborexant, Quviviq, daridorexant, Rozerem, ramelteon, and Silenor, low-dose doxepin. DailyMed. Accessed August 31, 2026.

5. U.S. National Library of Medicine. Current prescribing information for trazodone, quetiapine, gabapentin, and pregabalin extended release. DailyMed. Accessed August 31, 2026.

6. Baillargeon L, Landreville P, Verreault R, Beauchemin JP, Grégoire JP, Morin CM. Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial. CMAJ. 2003;169(10):1015-1020. PMID: 14609970. PMCID: PMC236226.

7. Morin CM, Bastien C, Guay B, Radouco-Thomas M, Leblanc J, Vallières A. Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia. American Journal of Psychiatry. 2004;161(2):332-342. doi:10.1176/appi.ajp.161.2.332. PMID: 14754783.

8. Takaesu Y, Utsumi T, Okajima I, et al. Psychosocial intervention for discontinuing benzodiazepine hypnotics in patients with chronic insomnia: a systematic review and meta-analysis. Sleep Medicine Reviews. 2019;48:101214. doi:10.1016/j.smrv.2019.101214. PMID: 31648145.

9. Fung CH, Martin JL, Dzierzewski JM, et al. Masked Taper With Behavioral Intervention for Discontinuation of Benzodiazepine Receptor Agonists: A Randomized Clinical Trial. JAMA Internal Medicine. 2024;184(12):1448-1456. doi:10.1001/jamainternmed.2024.5020. PMID: 39374004. PMCID: PMC11459364. ClinicalTrials.gov: NCT03687086.

10. Coteur K, Henrard G, Schoenmakers B, et al. Blended care to discontinue benzodiazepine receptor agonists use in patients with chronic insomnia disorder: a pragmatic cluster randomized controlled trial in primary care. Sleep. 2023;46(4):zsac278. doi:10.1093/sleep/zsac278. PMID: 36413221. ClinicalTrials.gov: NCT03937180.

11. Barbaux L, Cross NE, Perrault AA, et al. Effects of cognitive-behavioral therapy for insomnia during sedative-hypnotics withdrawal on sleep and cognition in older adults. Sleep Medicine. 2025;136:106826. doi:10.1016/j.sleep.2025.106826. PMID: 41092866. ISRCTN: ISRCTN10037794.

12. Zeraatkar D, Nagraj SK, Ling M, et al. Comparative effectiveness of interventions to facilitate deprescription of benzodiazepines and other sedative hypnotics: systematic review and meta-analysis. BMJ. 2025;389:e081336. doi:10.1136/bmj-2024-081336. PMID: 40527546. PMCID: PMC12171951.

13. 988 Suicide & Crisis Lifeline. Call, text, or chat 988. Substance Abuse and Mental Health Services Administration. 988 Suicide & Crisis Lifeline. America’s Poison Centers. Get help from Poison Control. Accessed August 31, 2026.

14. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2023;71(7):2052-2081. doi:10.1111/jgs.18372. PMID: 37139824. Full text.

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.